1. Generics Bulletin
  2. >>Products

Dr Reddy’s Launches Second US Vascepa Rival As Supreme Court Rejects Amarin

Appeal Refused In Litigation Involving Reddy’s And First-To-Market Hikma

 
• By Dave Wallace

Dr Reddy’s has shaken up the market for generic Vascepa in the US by launching its own icosapent ethyl capsules to compete with Hikma’s generic and the Amarin brand, hot on the heels of the Supreme Court’s rejection of the originator’s attempt to overturn a Federal Circuit decision invalidating six Vascepa patents.

Thumbs Up Thumbs Down
As the Supreme Court rejects Amarin, Dr Reddy’s launches a second generic • Source: Alamy

Dr Reddy’s has launched the second generic version of Amarin’s Vascepa (icosapent ethyl) 1g capsules in the US, putting it in direct competition with both the brand and Hikma’s first-to-market generic. The move comes immediately in the wake of the US Supreme Court denying the originator’s petition for certiorari review of a Federal Circuit decision that affirmed as invalid six patents shielding the purified fish oil brand.

The launch shakes up the generic icosapent ethyl market in the US, while also raising questions over supply of the generics given the constraints previously seen for the active pharmaceutical ingredient

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.